Trial Profile

An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 With or Without Chemotherapy in Patients With Metastatic/Unresectable Solid Tumors With FGFR2/3 Alterations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 061 (Primary) ; Lumipodlin (Primary) ; Capecitabine; Oxaliplatin
Indications Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Abbisko Therapeutics

26 Jun 2026 According to an Abbisko Therapeutics media release, As of January 2026, a total of 37 patients had been enrolled in this study.
26 Jun 2026 According to an Abbisko Therapeutics media release, data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
26 Jun 2026 Results presented in the Abbisko Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com